Engineering armored CAR-T cells to overcome the solid tumor microenvironment

Thursday 11:00 PDT / 14:00 EDT / 18:00 GMT / 19:00 CET

Sponsor

Engineering armored CAR-T cells to overcome the solid tumor microenvironment

Learn about a next-generation "armored" CAR-T cell strategy designed to deliver both cytokine modulation and checkpoint inhibition direct to the tumor.

This webinar presents preclinical data on an armored CAR-T cell strategy that secretes bifunctional fusion proteins directly within the tumor site, enabling localized immune modulation while limiting systemic toxicity.

Attendees will gain mechanistic insight and view comparative efficacy data demonstrating how targeted cytokine and checkpoint modulation can improve CAR-T cell infiltration, persistence, and anti-tumor activity in prostate and ovarian cancer models.

Drawing on findings from a recent peer-reviewed publication, the session will provide a clear framework for rational armored CAR-T design.

Join the webinar to:

Analyze comparative in vivo data demonstrating improved safety and anti-tumor efficacy of αPD-L1–IL-12–secreting CAR-T cells versus standard CAR-T and other fusion constructs, including TGFβ^trap and IL-15 variants
Understand mechanistic evidence showing enhanced T cell infiltration, localized IFNγ production, and reduced systemic inflammatory toxicity in prostate and ovarian tumor models
Apply a translational design framework for engineering CAR-T cells that co-deliver checkpoint inhibition and cytokine support within the TME
Evaluate analytical approaches for assessing armored T cell functionality in vitro and in vivo to support preclinical development and IND-enabling studies

Register now to examine data-driven strategies for enhancing CAR-T efficacy in solid tumors and informing the design of next-generation engineered T cell therapies.

Saul Priceman, PhD

Associate Professor of Medicine and Molecular Microbiology and Immunology at Keck School of Medicine, USC

Dr. Saul Priceman is an Associate Professor in the Department of Medicine at USC, and the Founding Director of the KSOM/Norris Center for Cancer Cellular Immunotherapy Research. Over the last 14 years, his research has focused on T cell immunobiology and cancer immunotherapies. Dr. Priceman’s laboratory develops CAR T cell therapies and combinatorial approaches for the treatment of solid cancers, bringing several therapies to phase 1 clinical testing. His research has led to high-impact publications in Nature Medicine, Nature Biomedical Engineering, Science Translational Medicine, and Nature Communications, with numerous patents and technologies licensed for further clinical development. Dr. Priceman’s research has been funded with grants from the National Cancer Institute, Department of Defense, California Institute for Regenerative Medicine, and the Prostate Cancer Foundation. He received his B.S. in microbiology at UCSB, his Ph.D. in molecular and medical pharmacology at UCLA, and his postdoctoral research at City of Hope.

In 33 Days

You have registered for this webinar